

Clinical Policy: Loncastuximab Tesirine-Ipyl (Zynlonta)

Reference Number: CP.PHAR.539

Effective Date: 09.01.21

Last Review Date: 08.26

Line of Business: Commercial, HIM/ICHRA, Medicaid

[Coding Implications](#)[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Loncastuximab tesirine-Ipyl (Zynlonta[®]) is a CD19-directed antibody and alkylating agent conjugate.

FDA Approved Indication(s)

Zynlonta is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Zynlonta is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Large B-Cell Lymphoma** (must meet all):

1. Diagnosis of large B-cell lymphoma (including DLBCL not otherwise specified, DLBCL arising from low-grade lymphoma, high-grade B-cell lymphoma, HIV-related DLBCL, primary effusion lymphoma, HHV8-positive DLBCL not otherwise specified, post-transplant lymphoproliferative disorders (PTLD), and histologic transformation of indolent lymphomas related to DLBCL);
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age $\geq$ 18 years;
4. Request meets one of the following (a or b):
 - a. Disease is refractory or member has relapsed after $\geq$ 2 lines of systemic therapy (*see Appendix B*);
 - b. Member is not a candidate for transplant and request is for second-line therapy for partial response, no response, or progressive disease following chemoimmunotherapy in patients with histologic transformation to DLBCL (off-label);

5. Prescribed as a single agent;
6. Request meets one of the following (a or b):*
 - a. Dose does not exceed 0.15 mg/kg IV every 3 weeks for 2 cycles, then 0.075 mg/kg every 3 weeks for subsequent cycles;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration:

Medicaid/HIM/ICHRA – 12 months

Commercial – 6 months or to the member's renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Large B-Cell Lymphoma (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Zynlonta for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed 0.075 mg/kg every 3 weeks;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration:

Medicaid/HIM/ICHRA – 12 months

Commercial – 6 months or to the member's renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

DLBCL: diffuse large B-cell lymphoma

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Examples of First-Line Treatment Regimens		
RCHOP (Rituxan [®] (rituximab), cyclophosphamide, doxorubicin, vincristine, prednisone)	Varies	Varies
RCEPP (Rituxan [®] (rituximab), cyclophosphamide, etoposide, prednisone, procarbazine)	Varies	Varies
RCDO (Rituxan [®] (rituximab), cyclophosphamide, liposomal doxorubicin, vincristine, prednisone)	Varies	Varies
DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicine) + Rituxan [®] (rituximab)	Varies	Varies

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
RCEOP (Rituxan [®] (rituximab), cyclophosphamide, etoposide, vincristine, prednisone)	Varies	Varies
RGCVP (Rituxan [®] , gemcitabine, cyclophosphamide, vincristine, prednisone)	Varies	Varies
Examples of Second-Line Treatment Regimens		
CEOP (cyclophosphamide, etoposide, vincristine, prednisone) ± Rituxan [®] (rituximab)	Varies	Varies
DHA (dexamethasone, cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin) ± Rituxan [®] (rituximab)		
DA-EPOCH ± Rituxan [®] (rituximab)	Varies	Varies
GDP (gemcitabine, dexamethasone, cisplatin) ± Rituxan [®] (rituximab)	Varies	Varies
gemcitabine, dexamethasone, carboplatin ± Rituxan [®] (rituximab)	Varies	Varies
GemOx (gemcitabine, oxaliplatin) ± Rituxan [®] (rituximab)	Varies	Varies
gemcitabine, vinorelbine ± Rituxan [®] (rituximab)	Varies	Varies
lenalidomide ± Rituxan [®] (rituximab)	Varies	Varies
Rituxan [®] (rituximab)	Varies	Varies
ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) ± Rituxan [®] (rituximab)	Varies	Varies
ICE (ifosfamide, carboplatin, etoposide) ± Rituxan [®] (rituximab)	Varies	Varies
MINE (mesna, ifosfamide, mitoxantrone, etoposide) ± Rituxan [®] (rituximab)	Varies	Varies
Polivy [®] (polatuzumab vedotin) ± bendamustine ± Rituxan [®] (rituximab)	Varies	Varies
Monjuvi [®] (tafasitamab-cxix) + lenalidomide	Varies	Varies
Yescarta [®] (axicabtagene ciloleucel)	Varies	Varies
Breyanzi [®] (lisocabtagene maralucecl)	Varies	Varies

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings
None reported

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Large B-cell lymphoma	0.15 mg/kg IV every 3 weeks for 2 cycles, then 0.075 mg/kg every 3 weeks for subsequent cycles	See regimen

VI. Product Availability

Lyophilized powder for reconstitution in a single-dose vial: 10 mg

VII. References

1. Zynlonta Prescribing Information. Murray Hill, NJ: ADC Therapeutics America; February 2026. Available at: www.zynlonta.com. Accessed April 13, 2026.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed May 16, 2026.
3. National Comprehensive Cancer Network. B-Cell Lymphomas Version 4.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed May 16, 2026.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9359	Injection, loncastuximab tesirine-lpyl, 0.075 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Template changes applied to other diagnoses/indications.	10.05.22	
3Q 2023 annual review: added Zynlonta prescribed as a single agent per NCCN; references reviewed and updated.	04.07.23	08.23
3Q 2024 annual review: revised language from “AIDS-related DLBCL” to “HIV-related DLBCL” to align with NCCN; added post-transplant lymphoproliferative disorders (PTLD) and histologic transformation of indolent lymphomas related to DLBCL as additional examples of large B-cell lymphoma; updated appendix B; references reviewed and updated.	05.06.24	08.24
3Q 2025 annual review: no significant changes; references reviewed and updated.	04.24.25	08.25
3Q 2026 annual review: no significant changes; added ICHRA line of business; revised initial approval durations from 6 months to 12 months; references reviewed and updated.	04.13.26	08.26

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health

plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2021 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise

published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.